Literature DB >> 14585629

The statin wars: why AstraZeneca must retreat.

.   

Abstract

Keywords:  AstraZeneca; Health Care and Public Health

Mesh:

Substances:

Year:  2003        PMID: 14585629

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Understanding adherence to official guidelines on statin prescribing in primary health care--a multi-level methodological approach.

Authors:  H Ohlsson; U Lindblad; T Lithman; B Ericsson; U-G Gerdtham; A Melander; L Råstam; J Merlo
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

2.  Facts and ideas from anywhere.

Authors:  William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-04

3.  Spiralling Medical Costs: Why Canada Needs NICE Medicine.

Authors:  Norman J Temple
Journal:  Healthc Policy       Date:  2007-11

4.  Statin wars following coronary revascularization--evidence-based clinical practice?

Authors:  James M Brophy; Vania Costa
Journal:  Can J Cardiol       Date:  2006-01       Impact factor: 5.223

5.  Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria.

Authors:  Jung-Im Shin; Derek M Fine; Yingying Sang; Aditya Surapaneni; Stephan C Dunning; Lesley A Inker; Thomas D Nolin; Alex R Chang; Morgan E Grams
Journal:  J Am Soc Nephrol       Date:  2022-07-19       Impact factor: 14.978

6.  Therapeutic traditions, patient socioeconomic characteristics and physicians' early new drug prescribing--a multilevel analysis of rosuvastatin prescription in south Sweden.

Authors:  Henrik Ohlsson; Basile Chaix; Juan Merlo
Journal:  Eur J Clin Pharmacol       Date:  2008-10-04       Impact factor: 2.953

Review 7.  Data mining of the public version of the FDA Adverse Event Reporting System.

Authors:  Toshiyuki Sakaeda; Akiko Tamon; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-04-25       Impact factor: 3.738

8.  Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.

Authors:  Toshiyuki Sakaeda; Kaori Kadoyama; Yasushi Okuno
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

9.  Understanding the effects of a decentralized budget on physicians' compliance with guidelines for statin prescription--a multilevel methodological approach.

Authors:  Henrik Ohlsson; Juan Merlo
Journal:  BMC Health Serv Res       Date:  2007-05-08       Impact factor: 2.655

Review 10.  Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes.

Authors:  Enas A Enas; Arun Kuruvila; Pravien Khanna; C S Pitchumoni; Viswanathan Mohan
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.